<DOC>
	<DOC>NCT00713817</DOC>
	<brief_summary>The purpose of this study is to assess the maintenance of effect after long-term treatment of Sativex® in subjects with neuropathic pain.</brief_summary>
	<brief_title>A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic Pain</brief_title>
	<detailed_description>A five week randomised-withdrawal phase (Part B) for a subset of subjects who took part in a 38 week, multicentre, open label (Part A) follow-on study to evaluate, the maintenance of effect of, the development of tolerance through exposure to, and safety of, Sativex® in the treatment of subjects with neuropathic pain. Subjects returned to the centre for an end of treatment visit at week 38 of Part A (Visit 5, Day 266), followed by Visits 5b (week 39), 5c (week 43) and an end of study visit took place 28 days after Visit 5c or withdrawal from the study.</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<criteria>Had participated in GWCL0404, was currently ongoing in the study (i.e. still receiving GW100002 treatment) and had completed the study up to Visit 5 Had complied with all of the study requirements todate, including the completion of the diary cards Had shown tolerability to the study medication in this study Ability (in the investigators opinion) and willingness to comply with all study requirements, including the completion of diary cards and study questionnaires Had experienced or was currently experiencing any adverse events or untoward medical occurrences which, in the opinion of the investigator, would prevent them from safely participating in this phase of the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Pain</keyword>
	<keyword>Peripheral Neuropathy</keyword>
</DOC>